The AZ HEROES longitudinal study on COVID-19 shows a decline in vaccine effectiveness from 91% prior to delta variant predominance to 66% afterward, suggesting an increased level of vaccination will be required to end the pandemic.

New data from an ongoing University of Arizona Health Sciences research study show that the COVID-19 vaccines remain effective following the predominance of the delta variant, although at a lower rate than prior to its emergence. The newly released findings from the longitudinal AZ HEROES research study at the Mel and Enid Zuckerman College of Public Health point to a need for more vaccinations to offset the decline in effectiveness.

Arizona’s COVID-19 outbreak is still widespread and medical experts say cases are rising at an alarming pace among children. The rate of cases among those 15 and younger is projected to surpass the rate of all other age groups in the state, according to data compiled by Joe Gerald, MD, PhD, an associate professor of public health policy and management at the Mel and Enid Zuckerman College of Public Health. "The age distribution of transmission is undergoing a profound shift," Dr. Gerald wrote Friday in his COVID-19 report.

Fariba Donovan, MD, PhD, assistant professor of medicine with the UArizona Valley Fever Center for Excellence in Tucson, says it’s crucial, now more than ever, for people with symptoms to get tested for Valley fever, because the symptoms are so similar to COVID-19. In fact, a third of all pneumonia cases in Valley fever endemic areas, like Southern Arizona, are due to Valley fever.

Maricopa County says it is continuing to offer community-based vaccine events across the area with various partners. The goal is to make access to the vaccine as easy as possible. "Remember in science, we need to be more conservative in waiting for the data and the evidence before we make a pronouncement too early. So, we can really be certain that at this point, it really is safe and effective," said Shad Marvasti, MD, assistant professor of family community and preventive medicine at the College of Medicine – Phoenix.

In this follow-up to her column about her cancer diagnosis, Dr. Taylor Riall explores how the experience led her to a new understanding of being a patient.

Health officials are warning against using a drug called ivermectin for unapproved use as a medicine to prevent or treat COVID-19. The drug, which has been approved only as an anti-parasitic treatment for humans and animals such as livestock and horses, has been the subject of a spike in calls to the Mississippi Poison Control Center. The Banner Poison and Drug Information Center in Phoenix and the UArizona Poison and Drug Information Center in Tucson have seen an increase in calls about ivermectin exposure and human use.

Like most of the United States, the Navajo Nation in the southwest has suffered dramatically, perhaps disproportionately, from the COVID pandemic. A University of Arizona Center for Rural Health report found that “more than a third of the people live without electricity, paved roads, cell phone service, landlines, safe housing, or other essentials of modern life.”

The top U.S. public health officials announced this week that all Americans can get a booster shot starting the third week of September. The federal guidance says adults over the age of 18 will be eligible for another dose of Pfizer or Moderna eight months after their second dose. Deepta Bhattacharya, PhD, professor of immunobiology at the University of Arizona College of Medicine – Tucson, said getting a booster soon after a second shot “raises the possibility that it won’t work that well.” He explained that third doses will likely work much better after fully vaccinated people lose some of the antibodies in their systems.